Stocks
Geron Corporation

Geron CorporationGERN

NASDAQHealthcareBiotechnology$0.87

Price as of · delayed, not real-time

A biopharmaceutical company focused on developing therapies for hematologic malignancies, with its lead product Rytelo (imetelstat) approved for lower-risk myelodysplastic syndromes. Investors track it for its commercial ramp and pipeline expansion in blood cancers.

52W Range: $0.84-$2.01

Congressional Interest in Geron Corporation (GERN)

1 member of Congress has disclosed 1 trade in Geron Corporation (GERN), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.

Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1

Who in Congress Is Trading GERN?

2004-12-10$1K-$15K
Stock